Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt
- First Posted Date
- 2024-09-09
- Last Posted Date
- 2024-09-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 58
- Registration Number
- NCT06588179
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-09-04
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 50
- Registration Number
- NCT06583837
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 44
- Registration Number
- NCT06578286
Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Breast Cancer
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT06578299
HTA of NIVATS Based on RWE
Recruiting
- Conditions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT06574295
- Locations
- 🇨🇳
School of Public Health, Fudan University, Shanghai, Shanghai, China
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-27
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT06572722
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 592
- Registration Number
- NCT06561620
- Locations
- 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease.
- First Posted Date
- 2024-08-20
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 36
- Registration Number
- NCT06561555
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
RCT on the Neurobehavioral Effects of Fruits and Vegetables in Shanghai Children
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 280
- Registration Number
- NCT06560359
- Locations
- 🇨🇳
School of public health, Fudan University, Shanghai, Shanghai, China
Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 260
- Registration Number
- NCT06561022
- Locations
- 🇨🇳
270 Dongan Road, Fudan University Shanghai Cancer Center, Shanghai, China
© Copyright 2024. All Rights Reserved by MedPath